← All peptidesPDA-V1 attestation Citations
verifiedBioGate · GREENGrade B
Retatrutide
YXQGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSTriple agonist at GLP-1, GIP, and glucagon receptors; Phase 2 demonstrated up to 24% body weight reduction at 48 weeks.
Aib²Aib¹³γGlu-C20 lipid sidechainamidated C-terminus
MW
4731.50
Length
39aa
Posterior
82.3%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · Aib²
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 5
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
6
Participants
526
Mean Δ
+0.15
Δ HRV ms (8-week) · 95% CI [-0.71, 1.02]
IPNFT · Molecule IPNFT V2Solana
Retatrutide
8a70a2…568770Royalty cascade
10.21%
Holders
113
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2023 · N Engl J Med
Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2)
Jastreboff AM et al.